Q1: 2026-04-29 Earnings Summary
EPS of -$1.37 misses by $0.46
|
Revenue of
$0.00
beats by $0.00
Viking Therapeutics, Inc. (VKTX) Q1 2026 Earnings Call April 29, 2026 4:30 PM EDT
Company Participants
Brian Lian - President, CEO & Director
Gregory Zante - Chief Financial Officer
Neil Aubuchon - Chief Commercial Officer
Conference Call Participants
Stephanie Diaz - Vida Strategic Partners, Inc.
Steven Seedhouse - Cantor Fitzgerald & Co., Research Division
Nathanael Charoensook - Leerink Partners LLC, Research Division
Michael Ulz - Morgan Stanley, Research Division
Ryan Deschner - Raymond James & Associates, Inc., Research Division
Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division
Biren Amin - Piper Sandler & Co., Research Division
Jay Olson - Oppenheimer & Co. Inc., Research Division
Tsan-Yu Hsieh - William Blair & Company L.L.C., Research Division
Jiale Song - Jefferies LLC, Research Division
William Wood - B. Riley Securities, Inc., Research Division
Hardik Parikh - JPMorgan Chase & Co, Research Division
Yale Jen - Laidlaw & Company (UK) Ltd., Research Division
Blake Gitler - BTIG, LLC, Research Division
Presentation
Operator
Welcome to the Viking Therapeutics First Quarter 2026 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded today, April 29, 2026. I would now like to turn the conference over to Viking's Manager of Investor Relations, Stephanie Diaz. Thank you, and over to you.
Stephanie Diaz
Vida Strategic Partners, Inc.
Hello, and thank you all for participating in today's call. Joining me today is Brian Lian, Viking's President and CEO; and Greg Zante, Viking's CFO.
Before we begin, I'd like to caution that comments made during this conference call today, April 29, 2026, will contain forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Viking's expectations regarding its development activities, time lines and milestones. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely and reported results should not be considered as an indication of
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。